INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 453m ago
HOUSE PTR53m ago
SEC 13F53m ago
ROBINHOOD CHAIN53m ago
SEC FORM 4/Tax withholdingVerified data

DeLucia David reported KYNB

Chief Financial Officer · KYNTRA BIO, INC. · Common Stock

Side
F
Value
$410
Shares
60
Price
$6.84
Executed
Mar 6, 2026
Disclosed
Mar 10, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Mar 6 executedMar 10, 2026 disclosed

KYNB · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Tax withholding — administrative, little informational value

  • Relative size+1 / 25

$410 reported value · 1.4% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · KYNB

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    11
    WT
    Wettig ThaneDirector, CEO
    KYNBKYNTRA BIO, INC.
    Tax withholding
    		F$1,787
    209 sh
    		Sep 6, 2026Sep 9, 2026
    traded Sep 6, 2026
    		+3dSEC FORM 4

    Evidence

    15
    DD
    DeLucia DavidChief Financial Officer
    KYNBKYNTRA BIO, INC.
    Tax withholding
    		F$188
    22 sh
    		Sep 6, 2026Sep 9, 2026
    traded Sep 6, 2026
    		+3dSEC FORM 4

    Evidence

    9
    DD
    DeLucia DavidChief Financial Officer
    KYNBKYNTRA BIO, INC.
    Tax withholding
    		F$349
    52 sh
    		Jun 6, 2026Jun 9, 2026
    traded Jun 6, 2026
    		+3dSEC FORM 4

    Evidence

    5
    WT
    Wettig ThaneDirector, CEO
    KYNBKYNTRA BIO, INC.
    Tax withholding
    		F$1,329
    198 sh
    		Jun 6, 2026Jun 9, 2026
    traded Jun 6, 2026
    		+3dSEC FORM 4

    Evidence

    9
    DD
    DeLucia DavidChief Financial Officer
    KYNBKYNTRA BIO, INC.
    Grant or award
    		A—
    26.0K sh
    		Feb 3, 2026Feb 5, 2026
    traded Feb 3, 2026
    		+2dSEC FORM 4

    Evidence

    5
    WT
    Wettig ThaneDirector, CEO
    KYNBKYNTRA BIO, INC.
    Grant or award
    		A—
    60.0K sh
    		Feb 3, 2026Feb 5, 2026
    traded Feb 3, 2026
    		+2dSEC FORM 4

    Evidence

    5
    WT
    Wettig ThaneDirector, CEO
    FGENKYNTRA BIO, INC.
    Tax withholding
    		F$2,181
    259 sh
    		Dec 6, 2025Dec 9, 2025
    traded Dec 6, 2025
    		+3dSEC FORM 4

    Evidence

    9
    DD
    DeLucia DavidChief Financial Officer
    FGENKYNTRA BIO, INC.
    Tax withholding
    		F$438
    52 sh
    		Dec 6, 2025Dec 9, 2025
    traded Dec 6, 2025
    		+3dSEC FORM 4

    Evidence

    29
    WT
    Wettig ThaneDirector, CEO
    FGENKYNTRA BIO, INC.
    Open-market purchase
    		BUY$9,180
    1,000 sh
    		Nov 13, 2025Nov 17, 2025
    traded Nov 13, 2025
    		+4dSEC FORM 4

    Evidence

    29
    WT
    Wettig ThaneDirector, CEO
    FGENKYNTRA BIO, INC.
    Open-market purchase
    		BUY$25K
    2,700 sh
    		Nov 17, 2025Nov 17, 2025
    traded Nov 17, 2025
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002040705-26-000003
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Mar 6, 2026
    Published
    Mar 10, 2026
    Ingested by INSIDER
    Nov 5, 04:12 UTC
    Last re-read
    Nov 5, 04:12 UTC

    Extracted facts

    Filer
    DeLucia David
    Role
    Chief Financial Officer
    Transaction
    Tax withholdingAs filed: “F”
    Asset
    KYNTRA BIO, INC.
    Ticker
    KYNB
    Shares
    60
    Price per share
    $6.84
    Value
    $410
    Execution date (reported)
    Mar 6, 2026
    Owned after transaction
    4,429 shares
    Days from execution to publication
    4

    Calculation

    Value = shares × reported price per share

    • Shares: 60
    • Price: $6.84

    = $410

    What this establishes

    DeLucia David filed this Form 4 reporting a tax withholding of KYNB on Mar 6, 2026. It became public on Mar 10, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Financial Officer
    DeLucia Davidcik:0002040705
    Issuer
    KYNTRA BIO, INC.cik:0000921299

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.